

Contents

Chapter	Page
1. Introduction and Summary	3
Background and Scope of the Study	3
Summary	4
Federal Activities	4
Reconsideration of the Cost Effectiveness of Vaccination Against Pneumococcal Pneumonia	5
Policy Implications	7
2. Reconsideration of the Cost Effectiveness of Vaccination Against Pneumococcal Pneumonia	11
Incidence of Pneumococcal Pneumonia	13
Proportion of Pneumococcal Pneumonia Caused by the Pneumococcal Types in the Vaccine	15
Efficacy Rate	16
Antibody Responses of High-Risk Groups With Chronic Disease	16
Antibody Responses of Immunocompromised People	17
Antibody Responses of Elderly People	17
Use With Influenza Vaccine	17
Comparison of Antibody Levels	17
Assessing Vaccine Efficacy	18
Duration of Immunity	20
Safety: Side Effects	20
Cost of Vaccination	21
Medical Costs unextended Years of Life	22
Reconsideration of the Cost-Effectiveness Results	23
Reconsideration of Costs to the Medicare Program	24
3. Federal Activities Regarding Appropriate Vaccine Use	27
Testing and Licensure of Pneumococcal Vaccine	27
Postmarketing Surveillance	27
Formulation of the 23-Valent Pneumococcal Vaccine	27
Testing and Licensure of the 23-Valent Vaccine	28
Research on pneumococcal Vaccine	29
Surveillance Activities	30
Recommendations for Use of Pneumococcal Vaccine	31
National Objective for 1990	31
4. Medicare Coverage of Pneumococcal Vaccine	37
Implementation of Medicare Coverage	37
Pneumococcal Vaccination Under Medicare Payment by Diagnosis Related Groups	39
Estimated Use of Pneumococcal Vaccine	39
Appendix A: Acknowledgments	45
References	49

Tables

Table No.	Page
1. Assumptions for OTA's Base Case and Sensitivity, 1978	12
2. Cost-Effectiveness Results With Lower Estimates for Incidence and Duration of Immunity and 1983 Relative Prices, for Pneumococcal Vaccinees > 65 Years	23

Table No.	Page
3. Estimated Net Medicare Expenditures for Pneumococcal Vaccinees > 65 Years, 1978 and 1983	24
4. Pneumococcal Types in the 14-Valent and 23-Valent Vaccines	28
5. Recommendations of the Immunization Practices Advisory Committee, 1978 and 1981	32
6. Total Sales of Pneumococcal Vaccine, Net of Returns, 1979-83	40
7. Persons in the United States With Certain High-Risk Conditions by Age, 1982	40
8. Physician Mentions of Pneumococcal Vaccine in the National Drug and Therapeutic Index, 1979-83	40
9. IMS America Data on Pneumococcal Vaccine Purchased by Hospitals and Drug Stores, 1978-82	40
10. Physician Mentions of Pneumococcal Vaccine in the National Drug and Therapeutic Index by Specialty	41
11. Physician Mentions of Pneumococcal Vaccine in the National Drug and Therapeutic Index by Physician Age, 1979-83	41
12. Physician Mentions of Pneumococcal Vaccine in the National Drug and Therapeutic Index by Patient Age, 1979-83	41
13. Diagnoses Associated With Physician Mentions of Pneumococcal Vaccine in the National Drug and Therapeutic Index, 1979-83	41
14. Physician Mentions of Pneumococcal Vaccine in the National Drug and Therapeutic Index by Month, 1979-83	42

Figure

Figure No.	Page
1. Announcement to Beneficiaries of Medicare Coverage of Pneumococcal Vaccine, January 1982	38